AIM: The aim of this study was to develop a vancomycin population pharmacokinetic model in adult obese patients and propose covariate-based dosing individualization in order to maximize the achievement of the newly recommended PK/PD target, according to a revised consensus guideline from 2020. METHODS: Therapeutic drug monitoring data from initial vancomycin therapy (first 3 days of treatment) in adult obese (BMI ≥ 30 kg/m2) patients from 2013 to 2022 were analyzed using a non-linear mixed-effects modeling method, and Monte Carlo simulations were then used to find the optimal dosage maximizing the PK/PD target attainment. RESULTS: A total of 147 vancomycin serum levels obtained from 138 patients were included in the analysis. Based on the covariate model diagnosis among all tested variables, no reliable predictor of vancomycin volume of distribution (Vd) was identified, while clearance (CL) was positively correlated with eGFR and lean body mass. Creatinine-based eGFR predicted vancomycin CL better than cystatin C-based eGFR. The median (interquartile range) value from conditional modes of individual estimates of Vd, CL, and elimination half-life in our population was 74.0 (70.5-75.4) L, 6.65 (4.95-8.42) L/h, and 7.7 (6.0-10.0) h, respectively. CONCLUSION: We proposed dosing individualization based on the covariate found in order to maximize the achievement of the newly recommended PK/PD target of the AUC/MIC ratio of 400-600. Clinical pharmacy/pharmacology interventions may lead to an improvement in vancomycin dosing with a reflection in PK/PD target attainment.

Department of Applied Pharmacy Faculty of Pharmacy Masaryk University Brno Czechia

Department of Clinical Pharmacy Bulovka University Hospital Prague Czechia

Department of Clinical Pharmacy Military University Hospital Prague Prague Czechia

Department of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czechia

Zobrazit více v PubMed

Adane E. D., Herald M., Koura F. (2015). Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections. Pharmacotherapy 35, 127–139. 10.1002/phar.1531 PubMed DOI

Boer P. (1984). Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am. J. Physiol. 247, F632–F636. 10.1152/ajprenal.1984.247.4.F632 PubMed DOI

Boutari C., Mantzoros C. S. (2022). A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism 133, 155217. 10.1016/j.metabol.2022.155217 PubMed DOI PMC

Carrero J. J., Fu E. L., Sang Y., Ballew S., Evans M., Elinder C. G., et al. (2023). Discordances between creatinine- and cystatin C-based estimated GFR and adverse clinical outcomes in routine clinical practice. Am. J. Kidney Dis. 82, 534–542. 10.1053/j.ajkd.2023.04.002 PubMed DOI

Chagnac A., Weinstein T., Korzets A., Ramadan E., Hirsch J., Gafter U. (2000). Glomerular hemodynamics in severe obesity. Am. J. Physiol. Ren. Physiol. 278, F817–F822. 10.1152/ajprenal.2000.278.5.F817 PubMed DOI

Craig W. A. (1998). Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26, 1–10. 10.1086/516284 PubMed DOI

Du Bois D., Du Bois E. F. (1989). A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5, 303–313. PubMed

Ducharme M. P., Slaughter R. L., Edwards D. J. (1994). Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther. Drug Monit. 16, 513–518. 10.1097/00007691-199410000-00013 PubMed DOI

European Committee on Antimicrobial Susceptibility Testing (2022). Clinical breakpoints - breakpoints and guidance. Available at: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_12.0_Breakpoint_Tables.pdf (Accessed November 22, 2023).

Gouju J., Legeay S. (2023). Pharmacokinetics of obese adults: not only an increase in weight. Biomed. Pharmacother. 166, 115281. 10.1016/j.biopha.2023.115281 PubMed DOI

Grace E. (2012). Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J. Antimicrob. Chemother. 67, 1305–1310. 10.1093/jac/dks066 PubMed DOI

Heble D. E., Jr., Mcpherson C., Nelson M. P., Hunstad D. A. (2013). Vancomycin trough concentrations in overweight or obese pediatric patients. Pharmacotherapy 33, 1273–1277. 10.1002/phar.1321 PubMed DOI

Hong J., Krop L. C., Johns T., Pai M. P. (2015). Individualized vancomycin dosing in obese patients: a two-sample measurement approach improves target attainment. Pharmacotherapy 35, 455–463. 10.1002/phar.1588 PubMed DOI

Inker L. A., Schmid C. H., Tighiouart H., Eckfeldt J. H., Feldman H. I., Greene T., et al. (2012). Estimating glomerular filtration rate from serum creatinine and cystatin C. N. Engl. J. Med. 367, 20–29. 10.1056/NEJMoa1114248 PubMed DOI PMC

Matzke G. R., Zhanel G. G., Guay D. R. (1986). Clinical pharmacokinetics of vancomycin. Clin. Pharmacokinet. 11, 257–282. 10.2165/00003088-198611040-00001 PubMed DOI

Miller M., Miller J. L., Hagemann T. M., Harrison D., Chavez-Bueno S., Johnson P. N. (2011). Vancomycin dosage in overweight and obese children. Am. J. Health Syst. Pharm. 68, 2062–2068. 10.2146/ajhp110107 PubMed DOI

Moise-Broder P. A., Forrest A., Birmingham M. C., Schentag J. J. (2004). Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43, 925–942. 10.2165/00003088-200443130-00005 PubMed DOI

Pai M. P. (2012). Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults. Pharmacotherapy 32, 856–868. 10.1002/j.1875-9114.2012.01108.x PubMed DOI

Rybak M. J. (2006). The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin. Infect. Dis. 42 (Suppl. 1), S35–S39. 10.1086/491712 PubMed DOI

Rybak M. J., Le J., Lodise T. P., Levine D. P., Bradley J. S., Liu C., et al. (2020). Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American society of health-system pharmacists, the infectious Diseases society of America, the pediatric infectious Diseases society, and the society of infectious Diseases pharmacists. Am. J. Health Syst. Pharm. 77, 835–864. 10.1093/ajhp/zxaa036 PubMed DOI

Rybak M. J., Lomaestro B. M., Rotschafer J. C., Moellering R. C., Jr., Craig W. A., Billeter M., et al. (2009). Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American society of health-system pharmacists, the infectious Diseases society of America, and the society of infectious Diseases pharmacists. Pharmacotherapy 29, 1275–1279. 10.1592/phco.29.11.1275 PubMed DOI

Shingde R. V., Graham G. G., Reuter S. E., Carland J. E., Day R. O., Stocker S. L. (2019). Comparison of the area under the curve for vancomycin estimated using compartmental and noncompartmental methods in adult patients with normal renal function. Ther. Drug Monit. 41, 726–731. 10.1097/FTD.0000000000000690 PubMed DOI

Sima M., Bakhouche H., Hartinger J., Cikankova T., Slanar O. (2019). Therapeutic drug monitoring of antibiotic agents: evaluation of predictive performance. Eur. J. Hosp. Pharm. 26, 85–88. 10.1136/ejhpharm-2017-001396 PubMed DOI PMC

Sima M., Hartinger J., Cikankova T., Slanar O. (2018a). Estimation of once-daily amikacin dose in critically ill adults. J. Chemother. 30, 37–43. 10.1080/1120009X.2017.1376818 PubMed DOI

Sima M., Hartinger J., Stenglova Netikova I., Slanar O. (2018b). Creatinine clearance estimations for vancomycin maintenance dose adjustments. Am. J. Ther. 25, e602–e604. 10.1097/MJT.0000000000000616 PubMed DOI

Sima M., Vodicka M., Maresova V., Salek T., Cabala R., Slanar O. (2017). Adherence with perindopril therapy: a pilot study using therapeutic drug monitoring of perindoprilat and an evaluation of the clearance estimation. Int. J. Clin. Pharm. 39, 1095–1100. 10.1007/s11096-017-0522-7 PubMed DOI

Smit C., De Hoogd S., Bruggemann R. J. M., Knibbe C. a. J. (2018). Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters. Expert Opin. Drug Metab. Toxicol. 14, 275–285. 10.1080/17425255.2018.1440287 PubMed DOI

Zhang T., Krekels E. H. J., Smit C., Van Dongen E. P. A., Bruggemann R. J. M., Knibbe C. A. J. (2023). How to dose vancomycin in overweight and obese patients with varying renal (Dys)function in the novel era of AUC 400-600 mg·h/L-Targeted dosing. Clin. Pharmacokinet. 63, 79–91. 10.1007/s40262-023-01324-5 PubMed DOI PMC